Marine Gilles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marine Gilles has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Florence Thirion
Université Paris-Saclay, INRAE, MGP
2 shared publications - Hervé Modeste Blottière
INRAE, UMR 1280, PhAN, Nantes Université, F-44000 Nantes, France
2 shared publications - Alexandre Famechon
Université Paris-Saclay, INRAE, MGP, Jouy-en-Josas, France
1 shared publication - Anne-Marie Davila
UMR PNCA, AgroParisTech, INRA, Université Paris-Saclay, Paris, France
1 shared publication - Anthony Henry Vernon Schapira
Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK
1 shared publication - Aymeric David
Aligning Science Across Parkinson s (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815; Universite Paris-Saclay, INRAE, MGP, 78350 Jouy-en-Josas, France
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2677951
Increasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk
Western dietary patterns, characterized by high intakes of red and processed meat, saturated fat, and refined carbohydrates, contribute substantially to the global burden of cardiometabolic disease...
- 27 May 2026
- Published by Taylor & Francis in Gut Microbes
- Vol. 18 (1) , 2677951
Open AccessIncreasing plant protein sources in the diet modulates gut microbiota and tryptophan metabolism in men at cardiometabolic risk
Western dietary patterns, characterized by high intakes of red and processed meat, saturated fat, and refined carbohydrates, contribute substantially to the global burden of cardiometabolic disease...
- Open Access
- 20 May 2026
- Published by Taylor & Francis in Gut Microbes Reports
- Vol. 3 (1)
Short-chain fructo-oligosaccharides modulate gut microbiota composition and metabolism: dose–response assessment in an ex vivo gut model
Short-chain fructo-oligosaccharides (scFOS) are prebiotic fiber rapidly fermented in the colon and known to stimulate beneficial bacteria, such as Bifidobacterium spp. and Lactobacillaceae. While their overall effects on the gut microbiota are established, the dose–response relationship remained only partially characterized. This study aimed to determine the minimum effective dose of scFOS required to modulate gut microbiota composition and functions. An ex vivo chemostat model was used to simulate colonic fermentation with different doses of scFOS (1 to 10 g/d). Microbiota composition and metabolic activity were assessed by qPCR, short-chain fatty acid (SCFA) quantification, and shotgun metagenomics. An increase in scFOS dose led to higher SCFA levels, particularly acetate and butyrate, along with a modification in microbial composition, with a minimum significant effective dose of 2.5 g/d. Significant increase in Bifidobacterium adolescentis, Anaerostipes hadrus, and Clostridium innocuum was observed at the same dose. Functional analysis revealed an enrichment of GH32 genes in the pangenomes of species positively impacted by scFOS. These findings demonstrate that low doses of scFOS can effectively modulate the gut microbiota and enhance SCFA production, supporting their use in dietary interventions aimed at improving intestinal health.
- 20 May 2026
- Published by Taylor & Francis in Gut Microbes Reports
- Vol. 3 (1)
Open AccessShort-chain fructo-oligosaccharides modulate gut microbiota composition and metabolism: dose–response assessment in an ex vivo gut model
Short-chain fructo-oligosaccharides (scFOS) are prebiotic fiber rapidly fermented in the colon and known to stimulate beneficial bacteria, such as Bifidobacterium spp. and Lactobacillaceae. While their overall effects on the gut microbiota are established, the dose–response relationship remained only partially characterized. This study aimed to determine the minimum effective dose of scFOS required to modulate gut microbiota composition and functions. An ex vivo chemostat model was used to simulate colonic fermentation with different doses of scFOS (1 to 10 g/d). Microbiota composition and metabolic activity were assessed by qPCR, short-chain fatty acid (SCFA) quantification, and shotgun metagenomics. An increase in scFOS dose led to higher SCFA levels, particularly acetate and butyrate, along with a modification in microbial composition, with a minimum significant effective dose of 2.5 g/d. Significant increase in Bifidobacterium adolescentis, Anaerostipes hadrus, and Clostridium innocuum was observed at the same dose. Functional analysis revealed an enrichment of GH32 genes in the pangenomes of species positively impacted by scFOS. These findings demonstrate that low doses of scFOS can effectively modulate the gut microbiota and enhance SCFA production, supporting their use in dietary interventions aimed at improving intestinal health.
- Open Access
Microbiome signature of Parkinson disease in healthy and genetically at-risk individuals
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.
Open AccessMicrobiome signature of Parkinson disease in healthy and genetically at-risk individuals
Summary: Parkinson disease (PD) is a major cause of disability with significant personal and system financial implications 1,2 . GBA1 variants are the commonest genetic risk factor for PD and increase the risk up to 30-fold 3,4 . Why only ∼20% of GBA1 variant carriers develop PD remains unknown. Here, by combining clinical and faecal metagenomics data from PD individuals carrying or not GBA1 variants, carriers of GBA1 variants not manifesting PD symptoms (GBA-NMC) and healthy controls, and using an innovative microbiome analysis, we show that a large component of the gut microbiome evolves from healthy across GBA-NMC towards PD and is strongly correlated with disease progression in patients, and prodromal symptoms suggestive of future development of PD in GBA-NMC. By using species altered in PD and GBA-NMC, we detect healthy individuals with the strongest prodromal PD clinical profile. These findings indicate that gut microbiome alterations can identify individuals with GBA1 variants most prone to develop PD and individuals in the general population that may be progressing towards PD. Healthy nutrition mitigates microbiome alterations associated with disease severity, suggesting that it could modify disease progression in PD patients and decrease the risk of disease development in healthy individuals including those with GBA1 variants.